Budesonide formoterol inhalation powder and tiotropium bromide powder mist are often used in combination with inhalation for the control of chronic obstructive pulmonary disease. Budesonide formoterol is a combination formulation Budesonide is an inhaled glucocorticoid with strong local anti-inflammatory and anti-allergic effects, relieving bronchial obstruction caused by rapid-onset and delayed-onset allergic reactions. Formoterol is a long-acting bronchodilator with diastolic effect on bronchial smooth muscle and relief of bronchospasm. Common adverse reactions to budesonide formoterol inhaler include tremor, palpitations, oropharyngeal candida infections, etc. It is contraindicated in drug-allergic patients and those who are allergic to inhaled lactose. Tiotropium belongs to anticholinergic long-acting bronchodilators, which has a different mechanism of action from budesonide formoterol, and it is a controlled drug for the treatment of COPD, chronic bronchitis and emphysema in clinical practice at present, applicable to the maintenance treatment in the stable period, which can effectively relieve dyspnea, improve lung function, and reduce the frequency of acute exacerbation of chronic obstructive pulmonary disease and the related hospitalization time. Common adverse reactions to tiotropium bromide powder inhaler include dry mouth, constipation, pharyngitis, sinusitis, candida infection, etc. It is contraindicated in people who are allergic to the drug, as well as those who are allergic to atropine and lactose. These two drugs are often used in combination in clinical practice to develop an inhalation therapy program for use in patients with severe chronic obstructive pulmonary disease or acute exacerbation, in order to improve the patient’s lung function, alleviate symptoms, reduce acute exacerbation, and the effect is better than a single drug. It is recommended to use the drugs in strict compliance with medical advice to control the condition.